Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights investors.invivyd.com/news-releases/…
investors.invivyd.com Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights | Invivyd DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communicated Updated data... Invivyd
Verified account This account is verified. Learn more@Invivyd
Invivyd is improving lives with medicines for serious infectious diseases. Pro-human. Anti-virus. Opposed to COVID and spike protein in all forms
648 Following 2.9K Followers 956 Posts
Latest posts 5
This week we’re headed to @ACRheum Convergence in Orlando, Florida.
Be sure to stop by booth #1806 to learn how antibody innovation may help protect patients with rheumatic conditions from viruses.
#ACR26 #rheumatology
Be sure to stop by booth #1806 to learn how antibody innovation may help protect patients with rheumatic conditions from viruses.
#ACR26 #rheumatology
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026 investors.invivyd.com/news-releases/…
investors.invivyd.com Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment... VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary... Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome investors.invivyd.com/news-releases/…
We’re excited to be joining the #infectiousdisease community in Washington D.C. for @IDWeekmtg! Our team will be sharing new insights on our monoclonal antibody candidate for the potential treatment and prevention of #measles.
If you’re planning to attend, visit us at booth #1743.
To learn more and register, visit: idweek2026.eventscribe.net
#IDWeek2026 #IDWeek #immunization
If you’re planning to attend, visit us at booth #1743.
To learn more and register, visit: idweek2026.eventscribe.net
#IDWeek2026 #IDWeek #immunization